Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/...

Descripción completa

Detalles Bibliográficos
Autores principales: Houwen, Cindy, van Lisdonk, Nico, Bolier, Jelle, van Eekeren, Michelle, van Gaalen, Mandy, van Herk, Aline, Paula, Zaïd, Peters, Natasja, den Reijer, Martijn, Mertens, Kelly, Thai, Khoa T.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124101/
https://www.ncbi.nlm.nih.gov/pubmed/37290260
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115970
_version_ 1785029777812357120
author Houwen, Cindy
van Lisdonk, Nico
Bolier, Jelle
van Eekeren, Michelle
van Gaalen, Mandy
van Herk, Aline
Paula, Zaïd
Peters, Natasja
den Reijer, Martijn
Mertens, Kelly
Thai, Khoa T.D.
author_facet Houwen, Cindy
van Lisdonk, Nico
Bolier, Jelle
van Eekeren, Michelle
van Gaalen, Mandy
van Herk, Aline
Paula, Zaïd
Peters, Natasja
den Reijer, Martijn
Mertens, Kelly
Thai, Khoa T.D.
author_sort Houwen, Cindy
collection PubMed
description We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.
format Online
Article
Text
id pubmed-10124101
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-101241012023-04-25 Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV Houwen, Cindy van Lisdonk, Nico Bolier, Jelle van Eekeren, Michelle van Gaalen, Mandy van Herk, Aline Paula, Zaïd Peters, Natasja den Reijer, Martijn Mertens, Kelly Thai, Khoa T.D. Diagn Microbiol Infect Dis Original Article We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV. Elsevier Inc. 2023-08 2023-04-24 /pmc/articles/PMC10124101/ /pubmed/37290260 http://dx.doi.org/10.1016/j.diagmicrobio.2023.115970 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Houwen, Cindy
van Lisdonk, Nico
Bolier, Jelle
van Eekeren, Michelle
van Gaalen, Mandy
van Herk, Aline
Paula, Zaïd
Peters, Natasja
den Reijer, Martijn
Mertens, Kelly
Thai, Khoa T.D.
Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title_full Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title_fullStr Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title_full_unstemmed Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title_short Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV
title_sort diagnostic performances of four commercially available assays for the identification of sars-cov-2, influenza type a/b virus and rsv
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124101/
https://www.ncbi.nlm.nih.gov/pubmed/37290260
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115970
work_keys_str_mv AT houwencindy diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT vanlisdonknico diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT bolierjelle diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT vaneekerenmichelle diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT vangaalenmandy diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT vanherkaline diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT paulazaid diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT petersnatasja diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT denreijermartijn diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT mertenskelly diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv
AT thaikhoatd diagnosticperformancesoffourcommerciallyavailableassaysfortheidentificationofsarscov2influenzatypeabvirusandrsv

Ejemplares similares